Home » Healthcare » Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market

Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market By Medication Type (Stimulant Medications, Non-Stimulant Medications, Combination Therapies) By Age groups (Pediatric Patients, Adult Patients) By Prescription status (Prescription Medications, Over-the-counter (OTC) Supplements) By Distribution Channels (Pharmacies and Drugstores, Hospital Pharmacies, Online Pharmacies) By ADHD Subtypes (Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, Combined Presentation) By Healthcare providers (Child Psychiatrists, Adult Psychiatrists, Pediatricians, Neurologists) – Growth, Share, Opportunities & Competitive Analysis, 2022-2030

Summary
Table Of Content

Market Insights

The Egyptian demand for ADHD (Attention Deficit Hyperactivity Disorder Drug) was valued at USD 47.86 million in 2022 and is expected to reach USD 67.12 million in 2030, growing at a CAGR of 4.37% between 2023 and 2030.
Stimulant medications are the leading segment by medication type, while combination therapies are expected to grow at a strong CAGR.
The leading age group segment is pediatric patients.
The CAGR for prescription medications is expected to be the highest during the projection period.
The pharmacies and drugstores category will likely have the highest CAGR during the forecast time frame.
The predominantly inattentive presentation segment is estimated to have the greatest CAGR during the forecast period.
The child psychiatrists segment will likely have the highest CAGR during the prediction period.

Advancements in diagnostic techniques, rising stress levels, expanding geriatric population, and improved healthcare infrastructure drive the Egypt ADHD (attention deficit hyperactivity disorder drug) market.
Expanding telepsychiatry for remote ADHD consultations, natural and herbal supplements, targeting the adult ADHD population with marketing and development initiatives, and creating patient education programs about ADHD and its management are the factors that impact the demand for Egypt’s ADHD (attention deficit hyperactivity disorder) market.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Executive Summary

Market Definition

The market for ADHD includes a variety of goods and services, as well as interventions, that are intended to address the different facets of ADHD. These include behavioral therapies, prescription drugs, educational aids, and other related healthcare services and products. Pharmaceutical companies, healthcare providers, mental health experts, educators, researchers, regulatory agencies, and advocacy groups are some of the stakeholders in the Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) market.

Market Overview

The market for Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) has been expanding steadily in recent years. Between 2023 and 2030, it is anticipated to rise at a CAGR of 4.37%. The market was estimated to be worth USD 47.86 million in 2022, and it is anticipated to be worth USD 67.12 million in 2030.

Improvements in diagnostic methods largely drive the market for medications treating attention deficit hyperactivity disorder (ADHD). Accurate diagnosis is crucial for effective treatment of ADHD, a neurodevelopmental disorder that affects both adults and children. New diagnostic tools make it possible to identify symptoms of ADHD early on, especially in children. Early identification makes Timely intervention and management possible, which lessens the severity of symptoms and enhances long-term results. The underlying neurobiology of ADHD is becoming better understood due to developments in diagnostic technologies like brain imaging and genetic testing. Genetic markers and neuroimaging are objective biomarkers for ADHD that improve diagnosis precision.

Improvements in diagnosis also lead to better ways to track how well ADHD drugs are working. By tracking changes in symptoms and modifying treatment plans accordingly, objective measures help healthcare providers optimize patient outcomes. Technology integration, such as mobile applications and digital health tools, can help monitor ADHD symptoms and provide useful information for patients and healthcare professionals.

Segmentation by Medication type

Stimulant medications are the market leader by medication type. ADHD is a neurodevelopmental disorder that can impede daily functioning and development due to persistent patterns of hyperactivity, impulsivity, and inattention. Among the most often prescribed drugs for treating the symptoms of ADHD are stimulant medications.
The combination therapies category will exhibit a sizable CAGR during the projected period. In the context of Attention Deficit Hyperactivity Disorder (ADHD), combination therapies refer to the use of several drugs or therapeutic approaches to treat the symptoms of ADHD more successfully than a single intervention.
Other medication types, such as non-stimulant medications, also contribute to the demand for ADHD in Egypt.

Segmentation by Age groups

The main age group category is pediatric patients. The market for ADHD medications for pediatric patients consists of medications that have been licensed for use in kids and teens to treat ADHD symptoms.
The adult patients category will likely register a significant CAGR during forecasting. The market for adult patients with ADHD has grown in prominence as more people are receiving diagnoses later in life and as awareness of adult ADHD has grown. Typically, medication, psychotherapy, and lifestyle changes are used to treat adult ADHD.

Segmentation by Prescription Status

The prescription medications category will experience the highest CAGR during the projection period. A variety of prescription drugs intended to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) are available on the market. A person’s ability to function daily may be greatly impacted by ADHD, a neurodevelopmental disorder marked by recurrent patterns of impulsivity, hyperactivity, and inattention.
Other prescription status, such as over-the-counter (OTC) supplements, also contribute to the demand for ADHD in Egypt.

Segmentation by Distribution Channels

Pharmacies and drugstores will likely have the highest CAGR during the projection period. Pharmacies and drugstores play a crucial role in the Egypt ADHD market by liaising between patients and healthcare professionals, supplying information, guaranteeing regulatory compliance, and improving patient care in general.
Other distribution channels, such as hospital pharmacies and online pharmacies, also contribute to the demand for ADHD in Egypt.

Segmentation by ADHD Subtypes

Predominantly inattentive presentation is expected to have the highest CAGR during the prediction period. Having trouble focusing, getting easily distracted, forgetting things, and having trouble staying organized are all signs of a predominantly inattentive presentation. While the hyperactivity and impulsivity typically associated with ADHD may not be present in those with this presentation, they may have difficulty focusing and finishing tasks.
Other ADHD subtypes, such as predominantly hyperactive-impulsive presentation and combined presentation, also contribute to the demand for Egypt ADHD.

Segmentation by Healthcare Providers

The category for child psychiatrists is anticipated to have the greatest CAGR throughout the forecast duration. Child psychiatrists are qualified to evaluate children’s psychological and behavioral problems. To diagnose ADHD, they utilize standardized criteria that take into account traits like impulsivity, hyperactivity, and inattention. To learn more about a child’s behavior, they may conduct observations, speak with parents and teachers, and use a variety of assessment instruments.
Other healthcare providers, such as adult psychiatrists, pediatricians, and neurologists, also contribute to the demand for Egypt’s ADHD.

A significant portion of the growth and expansion of the Egypt ADHD market can be attributed to research and development (R&D) expenditures. Neurodevelopmental disorders such as ADHD can impact both adults and children. It is typified by impulsivity, hyperactivity, and persistent patterns of inattention. There is an increasing need for novel and efficient treatments as knowledge of the illness grows, and new scientific discoveries are made. Pharmacies and academic institutions can investigate and find novel therapeutic approaches for treating ADHD with the help of research and development (R&D) investment. This might entail looking into the underlying neurobiological mechanisms causing ADHD, finding novel targets for drugs, and creating cutting-edge treatments that work better and cause fewer side effects.

Drug development must prioritize meeting regulatory requirements. To guarantee that new ADHD drugs fulfill the safety and efficacy standards set by regulatory bodies, research and development (R&D) expenditure is imperative for carrying out the required studies and experiments. A dedication to the long-term expansion and viability of the Egypt ADHD market is demonstrated by ongoing R&D spending. Organizations that allocate resources toward continuous research are more adept at adjusting to new scientific, technological, and fashion developments.

Key Highlights of the Report

The Egypt ADHD (attention deficit hyperactivity disorder drug) market is segmented by medication type, age groups, prescription status, distribution channels, ADHD subtypes, and healthcare providers. Stimulant medications are the market spearhead, and pediatric patients are the top age category. During the forecast period, the prescription medications category is expected to grow at the highest CAGR, and the pharmacies and drugstores category is anticipated to experience the highest CAGR.

Growing rates of attention deficit hyperactivity disorder are a major factor propelling the market for Egypt ADHD (attention deficit hyperactivity disorder drug). The general public, educators, and healthcare professionals have all become more aware of ADHD over time. A greater number of people are seeking medical attention for symptoms associated with ADHD as a result of this increased awareness, which has improved diagnosis rates. More precise diagnosis of ADHD has resulted from modifications to diagnostic standards and a deeper comprehension of the condition. A growing number of people who may not have previously received a diagnosis of ADHD are now being identified as having the disorder as a result of changes in diagnostic criteria.

Treatment options for ADHD have increased due to the development of new and improved medications. The market for Egypt ADHD may expand even more as a result of people being encouraged to seek pharmacological therapies by the availability of efficient medications with fewer adverse effects. ADHD may develop as a result of both environmental and genetic factors. The need for pharmacological interventions for ADHD may increase as more people at risk for the disorder are identified as a result of the growing understanding of the interaction between genetics and the environment.

Which Key Factors Are Driving The Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market?

Due to increased public and healthcare professional awareness of ADHD, partnerships and collaborations between pharmaceutical companies, and training programs to help healthcare professionals diagnose and treat ADHD more effectively, the market for ADHD (attention deficit hyperactivity disorder drug) is expanding in Egypt.

What Are The Key Challenges In The Egypt Market For ADHD (Attention Deficit Hyperactivity Disorder Drug)?

Several challenges, including disruptions in the supply chain, disparities in rural healthcare, stigma, and misconceptions, impede the growth of the Egypt ADHD (attention deficit hyperactivity disorder drug) market.

What Market Opportunities Exist For Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug)?

Supply chain optimization, clinical trials, personalized treatment options, and partnerships with healthcare providers create major opportunities for the Egypt ADHD (attention deficit hyperactivity disorder drug) market.

Market Drivers

Several factors influence the market for Egypt ADHD (attention deficit hyperactivity disorder drug). The main factors influencing the market for Egypt ADHD (attention deficit hyperactivity disorder drug) are as follows:

Growing Public and Governmental Awareness of Mental Health Issues

The market for Egypt ADHD (attention deficit hyperactivity disorder drug) may be considerably impacted by increased awareness of mental health conditions, such as attention deficit hyperactivity disorder. Increased awareness of mental health conditions, such as ADHD, may prompt more people to seek diagnosis and treatment. People who may have previously gone undiagnosed are more likely to seek professional help as awareness of the symptoms of ADHD grows. Consequently, there may be a rise in the market for Egypt’s ADHD drugs. Governments, advocacy organizations, and healthcare organizations are vital in educating the public about mental health issues through awareness campaigns. These advertisements could include information about the signs and symptoms of ADHD, the available treatments, and how important it is to get professional assistance. As more people become aware of their options, such initiatives may increase demand for ADHD medications. Governments may launch programs and policies to address mental health concerns after realizing how common and serious these problems are. This might entail more financing for mental health initiatives, awareness-raising campaigns, and laws that facilitate the availability of mental health services, including prescription drugs for disorders like ADHD. Increased awareness could lead to more research being done on mental health issues, such as ADHD. This might result in the creation of fresh, enhanced drugs, thereby growing the market for Egypt ADHD (attention deficit hyperactivity disorder drug).

Market Restraints

Several challenges could prevent the expansion of the Egyptian market for ADHD (attention deficit hyperactivity disorder drug). Among them are the following:

Scarcity of Well-Performing and Tolerant ADHD Drugs

People of all ages can be affected by ADHD, and not everyone responds well to the current treatments. For instance, a drug that suits adults well might not be appropriate for kids, and vice versa. When managing pediatric cases, where the choice of medications may be more restricted due to safety concerns, limited treatment options can be especially difficult. Anxiety and depression are common comorbidities among people with ADHD. Attempting to manage the intricacies of these coexisting disorders can be difficult when treatment options are limited. It would be advantageous to provide a wider variety of treatment options to meet the various needs of people with ADHD and co-occurring conditions. A patient’s tolerance to medication may build up over time, making the treatment less effective for some people living with ADHD who don’t respond well to it. Restricted options refer to the reduced number of options available to patients and healthcare providers if the medication initially proves ineffective or has unbearable side effects. A stagnant market with little innovation may arise from a lack of funding for research and development of new ADHD medications. Patients have few options when no ground-breaking treatments are available to promote the development of more potent and well-tolerated medications.

Opportunities

The Egypt market for ADHD (attention deficit hyperactivity disorder drug) presents significant potential opportunities. The following is an example of these:

Collaboration with Mental Health Professionals

Due to the complexity of ADHD, a multifaceted approach to treatment is frequently necessary. A more comprehensive and integrated care model is made possible through collaboration with mental health specialists, such as psychologists, psychiatrists, and therapists. Combining behavioral therapies, counseling, and psychoeducation with pharmaceutical interventions is one way to achieve this. When evaluating the special needs of people with ADHD, mental health specialists can be extremely helpful. Because of their experience, individualized treatment plans can be created that address not just the symptoms of ADHD but also any co-occurring mental health issues or psychosocial issues that may affect the patient’s quality of life.

Behavioral interventions are a crucial part of managing ADHD in addition to medication. Working together with mental health providers makes it possible to apply research-proven behavioral techniques to address particular ADHD-related issues like impulsivity, inattention, and hyperactivity. Mental health specialists can carry out comprehensive evaluations to find any coexisting mental health issues, such as depression or anxiety, that may be present in addition to ADHD. This can direct the choice of suitable treatment modalities and enhance overall results. They encourage cooperation, resulting in an integrated healthcare system where specialists collaborate easily. This can enhance care coordination, communication, and general ADHD management effectiveness. Pharmaceutical companies can stand out by actively collaborating with mental health professionals. Establishing robust collaborations with respectable mental health establishments or professionals can augment the legitimacy and stature of ADHD drugs.

Competitive Landscape

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Players

The Egypt market for ADHD (attention deficit hyperactivity disorder drug) is very competitive, with many powerful players. Some of the leading market participants and their corresponding market shares are listed below:

Amneal Pharmaceuticals, Inc.
Eli Lilly And Company
Janssen Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc.
RespireRx Pharmaceuticals Inc.
Otsuka Pharmaceutical Co., Ltd
Neos Therapeutics, Inc.
American Brivision (Holding) Corporation
Novartis International AG
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Purdue Pharma L.P
Others

These companies prioritize mergers and acquisitions, expanding their distribution network, and developing new products to remain competitive.

The leading competitors in the Egypt ADHD market constantly seek an advantage by releasing new products and advancements.

In September 2022, Cingulate Inc. released CTx-2103, the company’s asset for treating anxiety-related illnesses. The non-benzodiazepine medication CTx-2103, which contains the active pharmacological ingredient buspirone hydrochloride, has not been shown to cause dependence or to be dangerous if it does. It is advised that patients take buspirone several times a day to manage their anxiety; however, because of its short half-life, this can be challenging for them and may lead to less-than-ideal treatment outcomes.

In February 2022, Noven’s Xelstrym (dextroamphetamine) transdermal system was approved by the Food and Drug Administration to treat attention-deficit hyperactivity disorder (ADHD) in adults and children aged six and up.

Summary of Key Findings

The Egypt ADHD market continues to grow due to the increasing number of over-the-counter (OTC) products.
The market is segmented by medication type, age group, prescription status, distribution channels, ADHD subtypes, and healthcare providers.
Stimulant medications are the most preferred medication type in the market.
Pediatric patients are the most common in terms of age groups.
Regarding CAGR, prescription medications are expected to grow fastest during the forecast period.
The category for child psychiatrists will likely see the highest CAGR during the anticipated time frame.
The Egypt ADHD (attention deficit hyperactivity disorder drug) market is highly competitive, with key players including Amneal Pharmaceuticals, Inc., Eli Lilly And Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Purdue Pharma L.P, and others.

Future Outlook

Optimistic viewpoint for the Egypt ADHD (attention deficit hyperactivity disorder drug) industry with noteworthy growth potential.
One of the key elements propelling the growth of the ADHD (attention deficit hyperactivity disorder drug) market in Egypt is the digital health platforms.
During the projected period, the economic factors might significantly challenge the market’s expansion.
Foremost companies must concentrate on product innovation, expanding their market reach, and maintaining competitive pricing to stay ahead.

Segmentation

By Medication type
- Stimulant Medications
- Non-Stimulant Medications
- Combination Therapies
By Age groups
- Pediatric Patients
- Adult Patients
By Prescription status
- Prescription Medications
- Over-the-counter (OTC) Supplements
By Distribution Channels
- Pharmacies and Drugstores
- Hospital Pharmacies
- Online Pharmacies
By ADHD Subtypes
- Predominantly Inattentive Presentation
- Predominantly Hyperactive-Impulsive Presentation
- Combined Presentation
By Healthcare providers
- Child Psychiatrists
- Adult Psychiatrists
- Pediatricians
- Neurologists

Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market
2.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Medication Type
2.1.2. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Age Groups
2.1.3. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Prescription Status
2.1.4. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Distribution Channels
2.1.5. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By ADHD Subtypes
2.1.6. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Healthcare Providers
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Drivers
3.2.2. ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Restraints
3.2.3. ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Opportunities
3.2.4. Major ADHD (Attention Deficit Hyperactivity Disorder Drug) Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Medication Type
3.5.2. Age Groups
3.5.3. Prescription Status
3.5.4. Distribution Channels
3.5.5. ADHD Subtypes
3.5.6. Healthcare Providers
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Company Market Share, Value 2022
4.1.2. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Top 6 Company Market Share, Value 2022
4.1.3. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Top 3 Company Market Share, Value 2022
4.2. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the Egypt Market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Impact Analysis
7.2.5.1. Egypt
8. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Medication Type
8.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by Medication Type
8.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By Medication Type, 2022 Vs 2030 (in %)
8.2. Stimulant Medications
8.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Stimulant Medications, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for Stimulant Medications
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Non-Stimulant Medications
8.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Non-Stimulant Medications, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for Non-Stimulant Medications
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Combination Therapies
8.4.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Combination Therapies, 2017-2030 (US$ Mn)
8.4.2. Market Dynamics for Combination Therapies
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
9. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Age Groups
9.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by Age Groups
9.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By Age Groups, 2022 Vs 2030 (in %)
9.2. Pediatric Patients
9.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Pediatric Patients, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for Pediatric Patients
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Adult Patients
9.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Adult Patients, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for Adult Patients
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
10. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Prescription Status
10.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by Prescription Status
10.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By Prescription Status, 2022 Vs 2030 (in %)
10.2. Prescription Medications
10.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Prescription Medications, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for Prescription Medications
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Over-the-Counter (OTC) Supplements
10.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Over-the-Counter (OTC) Supplements, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Over-the-Counter (OTC) Supplements
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
11. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Distribution Channels
11.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by Distribution Channels
11.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By Distribution Channels, 2022 Vs 2030 (in %)
11.2. Pharmacies and Drugstores
11.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Pharmacies and Drugstores, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Pharmacies and Drugstores
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Hospital Pharmacies
11.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Hospital Pharmacies, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Hospital Pharmacies
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Online Pharmacies
11.4.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Online Pharmacies, 2017-2030 (US$ Mn)
11.4.2. Market Dynamics for Online Pharmacies
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
12. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By ADHD Subtypes
12.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by ADHD Subtypes
12.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By ADHD Subtypes, 2022 Vs 2030 (in %)
12.2. Predominantly Inattentive Presentation
12.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Predominantly Inattentive Presentation, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for Predominantly Inattentive Presentation
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Predominantly Hyperactive-Impulsive Presentation
12.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Predominantly Hyperactive-Impulsive Presentation, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Predominantly Hyperactive-Impulsive Presentation
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Combined Presentation
12.4.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Combined Presentation, 2017-2030 (US$ Mn)
12.4.2. Market Dynamics for Combined Presentation
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
13. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Healthcare Providers
13.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Overview, by Healthcare Providers
13.1.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Revenue Share, By Healthcare Providers, 2022 Vs 2030 (in %)
13.2. Child Psychiatrists
13.2.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Child Psychiatrists, 2017-2030 (US$ Mn)
13.2.2. Market Dynamics for Child Psychiatrists
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Adult Psychiatrists
13.3.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Adult Psychiatrists, 2017-2030 (US$ Mn)
13.3.2. Market Dynamics for Adult Psychiatrists
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends
13.4. Pediatricians
13.4.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Pediatricians, 2017-2030 (US$ Mn)
13.4.2. Market Dynamics for Pediatricians
13.4.2.1. Drivers
13.4.2.2. Restraints
13.4.2.3. Opportunities
13.4.2.4. Trends
13.5. Neurologists
13.5.1. Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, By Neurologists, 2017-2030 (US$ Mn)
13.5.2. Market Dynamics for Neurologists
13.5.2.1. Drivers
13.5.2.2. Restraints
13.5.2.3. Opportunities
13.5.2.4. Trends
14. Company Profiles
14.1. Amneal Pharmaceuticals, Inc.
14.1.1. Company Overview
14.1.2. Products/Services Portfolio
14.1.3. Geographical Presence
14.1.4. SWOT Analysis
14.1.5. Financial Summary
14.1.5.1. Market Revenue and Net Profit (2019-2022)
14.1.5.2. Business Segment Revenue Analysis
14.1.5.3. Geographical Revenue Analysis
14.2. Eli Lilly And Company
14.3. Janssen Pharmaceuticals, Inc.
14.4. Noven Pharmaceuticals, Inc.
14.5. RespireRx Pharmaceuticals Inc.
14.6. Otsuka Pharmaceutical Co., Ltd
14.7. Neos Therapeutics, Inc.
14.8. American Brivision (Holding) Corporation
14.9. Novartis International AG
14.10. Takeda Pharmaceutical Company Limited
14.11. GlaxoSmithKline plc
14.12. Purdue Pharma L.P
14.13. Others
15. Research Methodology
15.1. Research Methodology
15.2. Phase I – Secondary Research
15.3. Phase II – Data Modelling
15.3.1. Company Share Analysis Model
15.3.2. Revenue Based Modelling
15.4. Phase III – Primary Research
15.5. Research Limitations
15.5.1. Assumptions

List of Figures
FIG. 1 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Segmentation
FIG. 4 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Medication Type, 2022 (US$ Mn)
FIG. 5 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Age Groups, 2022 (US$ Mn)
FIG. 6 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Status, 2022 (US$ Mn)
FIG. 7 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Distribution Channels, 2022 (US$ Mn)
FIG. 8 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by ADHD Subtypes, 2022 (US$ Mn)
FIG. 9 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Healthcare Providers, 2022 (US$ Mn)
FIG. 10 Attractive Investment Proposition, by Medication Type, 2022
FIG. 11 Attractive Investment Proposition, by Age Groups, 2022
FIG. 12 Attractive Investment Proposition, by Prescription Status, 2022
FIG. 13 Attractive Investment Proposition, by Distribution Channels, 2022
FIG. 14 Attractive Investment Proposition, by ADHD Subtypes, 2022
FIG. 15 Attractive Investment Proposition, by Healthcare Providers, 2022
FIG. 16 Egypt Market Share Analysis of Key ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Manufacturers, 2022
FIG. 17 Egypt Market Positioning of Key ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Manufacturers, 2022
FIG. 18 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By Medication Type, 2022 & 2030 (Value %)
FIG. 19 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Stimulant Medications, Value, 2017-2030 (US$ Mn)
FIG. 20 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Non-Stimulant Medications, Value, 2017-2030 (US$ Mn)
FIG. 21 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combination Therapies, Value, 2017-2030 (US$ Mn)
FIG. 22 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By Age Groups, 2022 & 2030 (Value %)
FIG. 23 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatric Patients, Value, 2017-2030 (US$ Mn)
FIG. 24 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Patients, Value, 2017-2030 (US$ Mn)
FIG. 25 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By Prescription Status, 2022 & 2030 (Value %)
FIG. 26 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Medications, Value, 2017-2030 (US$ Mn)
FIG. 27 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Over-the-Counter (OTC) Supplements, Value, 2017-2030 (US$ Mn)
FIG. 28 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By Distribution Channels, 2022 & 2030 (Value %)
FIG. 29 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pharmacies and Drugstores, Value, 2017-2030 (US$ Mn)
FIG. 30 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Mn)
FIG. 31 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Online Pharmacies, Value, 2017-2030 (US$ Mn)
FIG. 32 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By ADHD Subtypes, 2022 & 2030 (Value %)
FIG. 33 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Inattentive Presentation, Value, 2017-2030 (US$ Mn)
FIG. 34 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Hyperactive-Impulsive Presentation, Value, 2017-2030 (US$ Mn)
FIG. 35 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combined Presentation, Value, 2017-2030 (US$ Mn)
FIG. 36 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market Value Contribution, By Healthcare Providers, 2022 & 2030 (Value %)
FIG. 37 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Child Psychiatrists, Value, 2017-2030 (US$ Mn)
FIG. 38 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Psychiatrists, Value, 2017-2030 (US$ Mn)
FIG. 39 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatricians, Value, 2017-2030 (US$ Mn)
FIG. 40 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Neurologists, Value, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market
TABLE 2 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Market Drivers Impact Analysis
TABLE 3 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market: Market Restraints Impact Analysis
TABLE 4 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Competitive Benchmarking, 2022
TABLE 5 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Geographical Presence Analysis, 2022
TABLE 6 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Key Strategies Analysis, 2022
TABLE 7 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Stimulant Medications, 2017-2022 (US$ Mn)
TABLE 8 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Stimulant Medications, 2023-2030 (US$ Mn)
TABLE 9 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Non-Stimulant Medications, 2017-2022 (US$ Mn)
TABLE 10 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Non-Stimulant Medications, 2023-2030 (US$ Mn)
TABLE 11 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combination Therapies, 2017-2022 (US$ Mn)
TABLE 12 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combination Therapies, 2023-2030 (US$ Mn)
TABLE 13 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatric Patients, 2017-2022 (US$ Mn)
TABLE 14 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatric Patients, 2023-2030 (US$ Mn)
TABLE 15 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Patients, 2017-2022 (US$ Mn)
TABLE 16 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Patients, 2023-2030 (US$ Mn)
TABLE 17 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Medications, 2017-2022 (US$ Mn)
TABLE 18 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Medications, 2023-2030 (US$ Mn)
TABLE 19 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Over-the-Counter (OTC) Supplements, 2017-2022 (US$ Mn)
TABLE 20 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Over-the-Counter (OTC) Supplements, 2023-2030 (US$ Mn)
TABLE 21 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pharmacies and Drugstores, 2017-2022 (US$ Mn)
TABLE 22 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pharmacies and Drugstores, 2023-2030 (US$ Mn)
TABLE 23 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Hospital Pharmacies, 2017-2022 (US$ Mn)
TABLE 24 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Hospital Pharmacies, 2023-2030 (US$ Mn)
TABLE 25 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Online Pharmacies, 2017-2022 (US$ Mn)
TABLE 26 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Online Pharmacies, 2023-2030 (US$ Mn)
TABLE 27 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Inattentive Presentation, 2017-2022 (US$ Mn)
TABLE 28 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Inattentive Presentation, 2023-2030 (US$ Mn)
TABLE 29 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Hyperactive-Impulsive Presentation, 2017-2022 (US$ Mn)
TABLE 30 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Predominantly Hyperactive-Impulsive Presentation, 2023-2030 (US$ Mn)
TABLE 31 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combined Presentation, 2017-2022 (US$ Mn)
TABLE 32 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Combined Presentation, 2023-2030 (US$ Mn)
TABLE 33 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Child Psychiatrists, 2017-2022 (US$ Mn)
TABLE 34 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Child Psychiatrists, 2023-2030 (US$ Mn)
TABLE 35 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Psychiatrists, 2017-2022 (US$ Mn)
TABLE 36 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Adult Psychiatrists, 2023-2030 (US$ Mn)
TABLE 37 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatricians, 2017-2022 (US$ Mn)
TABLE 38 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Pediatricians, 2023-2030 (US$ Mn)
TABLE 39 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Neurologists, 2017-2022 (US$ Mn)
TABLE 40 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Neurologists, 2023-2030 (US$ Mn)
TABLE 41 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Medication Type, 2017-2022 (US$ Mn)
TABLE 42 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Medication Type, 2023-2030 (US$ Mn)
TABLE 43 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Age Groups, 2017-2022 (US$ Mn)
TABLE 44 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Age Groups, 2023-2030 (US$ Mn)
TABLE 45 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Status, 2017-2022 (US$ Mn)
TABLE 46 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Prescription Status, 2023-2030 (US$ Mn)
TABLE 47 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Distribution Channels, 2017-2022 (US$ Mn)
TABLE 48 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Distribution Channels, 2023-2030 (US$ Mn)
TABLE 49 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by ADHD Subtypes, 2017-2022 (US$ Mn)
TABLE 50 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by ADHD Subtypes, 2023-2030 (US$ Mn)
TABLE 51 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Healthcare Providers, 2017-2022 (US$ Mn)
TABLE 52 Egypt ADHD (Attention Deficit Hyperactivity Disorder Drug) Market, by Healthcare Providers, 2023-2030 (US$ Mn)

How big is the Egyptian market for ADHD (attention deficit hyperactivity disorder drug) right now?

In 2022, the Egypt ADHD (attention deficit hyperactivity disorder drug) market was estimated to be worth USD 47.86 million.

What is the anticipated growth rate of the Egypt ADHD (attention deficit hyperactivity disorder drug) market from 2023 to 2030?

The market for Egypt ADHD (attention deficit hyperactivity disorder drug) is anticipated to increase at a CAGR of 4.37% from 2023 to 2030, reaching USD 67.12 million in 2030.

Which market category is in the lead for the medication type?

Stimulant medications are the most popular category of medication type.

Which segment is leading the market in terms of age groups?

The notable segment is pediatric patients by age group.

Which prescription status segment is estimated to have the highest CAGR throughout the forecast period?

The prescription medications category is anticipated to exhibit the highest CAGR during the projection period.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –